We’ve recently updated our valuation analysis.

Creo Medical Group Valuation

Is CREO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CREO?

Other financial metrics that can be useful for relative valuation.

CREO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA-0.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CREO's PS Ratio compare to its peers?

The above table shows the PS ratio for CREO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.4x
IHC Inspiration Healthcare Group
NSCI NetScientific
YGEN Yourgene Health
SMD Spectral MD Holdings
CREO Creo Medical Group

Price-To-Sales vs Peers: CREO is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (4.4x).

Price to Earnings Ratio vs Industry

How does CREO's PE Ratio compare vs other companies in the GB Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.1%

Price-To-Sales vs Industry: CREO is good value based on its Price-To-Sales Ratio (1.4x) compared to the UK Medical Equipment industry average (2.8x)

Price to Sales Ratio vs Fair Ratio

What is CREO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CREO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: CREO is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).

Share Price vs Fair Value

What is the Fair Price of CREO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CREO (£0.2) is trading below our estimate of fair value (£1.1)

Significantly Below Fair Value: CREO is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies